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Abstract Spinocerebellar ataxia type 7 (SCA7) is one of
nine neurodegenerative disorders caused by expanded poly-
glutamine repeats, and a common toxic gain-of-function
mechanism has been proposed. Proteolytic cleavage of sev-
eral polyglutamine proteins has been identified and sug-
gested to modulate the polyglutamine toxicity. In this
study, we show that full-length and cleaved fragments of
the SCA7 disease protein ataxin-7 (ATXN7) are differen-
tially degraded. We found that the ubiquitin–proteosome
system (UPS) was essential for the degradation of full-
length endogenous ATXN7 or transgenic full-length
ATXN7 with a normal or expanded glutamine repeat in both
HEK 293T and stable PC12 cells. However, a similar con-
tribution by UPS and autophagy was found for the degra-
dation of proteolytically cleaved ATXN7 fragments.
Furthermore, in our novel stable inducible PC12 model,
induction of mutant ATXN7 expression resulted in toxicity
and this toxicity was worsened by inhibition of either UPS
or autophagy. In contrast, pharmacological activation of
autophagy could ameliorate the ATXN7-induced toxicity.
Based on our findings, we propose that both UPS and
autophagy are important for the reduction of mutant
ataxin-7-induced toxicity, and enhancing ATXN7 clearance
through autophagy could be used as a potential therapeutic
strategy in SCA7.
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Abbreviations
ATXN7 Ataxin-7
GFP Green fluorescence protein
HD Hungtinton’s disease
kDa Kilodalton
PolyQ Polyglutamine
Q Glutamine
SCA7 Spinocerebellar ataxia type 7
STAGA SPT3-TAF(II)31-GCN5L acetylase
UPS Ubiquitin–proteasome system
Introduction
Spinocerebellar ataxia type 7 (SCA7) is an autosomal dom-
inant neurodegenerative disorder characterized by neuronal
death in the retina, cerebellum, and brainstem (Harding and
Deufel 1993). The disease is caused by expansion of an
unstable CAG repeat in the 5′-end of the SCA7 gene result-
ing in an expanded polyglutamine domain in the ataxin-7
(ATXN7) protein (David et al. 1997). ATXN7 is a widely
expressed protein (Jonasson et al. 2002; Lindenberg et al.
2000) and a subunit of the STAGA (SPT3-TAF(II)31-
GCN5L acetylase) complex (Helmlinger et al. 2004; Palhan
et al. 2005). STAGA regulates transcription through
its histone acetylation and de-ubiquitination activity
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DOI 10.1007/s12031-012-9722-8(Helmlinger et al. 2004; McCullough and Grant 2010;
Palhan et al. 2005). However, the exact role of ATXN7
in STAGA and how this function is affected by the polyglut-
amine expansion are still unclear (for review, see
McCullough and Grant 2010).
Besides SCA7, eight other neurodegenerative disorders
including Huntington’s disease (HD), dentatorubral pallid-
olusian atrophy, spinal bulbar muscular atrophy, and SCA1-
3, 6, and 17, caused by CAG/glutamine expansions, have
been identified (Katsuno et al. 2008). These disorders are
commonly known as polyglutamine (polyQ) diseases and
are characterized by aggregation of the expanded polyQ
protein into nuclear and/or cytoplasmic inclusions in the
neurons of patients. Several studies have suggested that
proteins containing expanded polyQ domains misfold and
assume an abnormal β-sheet conformation which results in
their aggregation (for review, see Hands and Wyttenbach
2010). A correlation between the ability of the polyglut-
amine protein to aggregate and cause toxicity has been
shown; however, whether misfolded monomers, oligomers,
or large inclusions are the major toxic species is still unclear
(Davies and Scherzinger 1997; Hands and Wyttenbach
2010; Scherzinger et al. 1999).
Protein degradation systems are crucial for clearance of
damaged and misfolded proteins which could cause cellular
toxicity. The ubiquitin–proteasome system (UPS) and
autophagy are the two main protein degradation pathways
in mammalian cells (for review, see Wong and Cuervo
2010b). UPS mainly degrades short-lived proteins in a
two-step process: (1) the enzyme catalyzed attachment of
multiple ubiquitin molecules to the target protein, which
signals its targeting to cytoplasmic or nuclear proteasomes,
and (2) degradation of the ubiquitinated target protein by the
26S proteasome (Wong and Cuervo 2010b). Mutant poly-
glutamine proteins have been reported to be resistant to UPS
clearance and even disrupt UPS activity (Bence et al. 2001;
Bennett et al. 2007; Holmberg et al. 2004; Jana et al. 2001;
Verhoef et al. 2002). However, other studies have ques-
tioned these findings (Iwata et al. 2009; Maynard et al.
2009; Michalik and Van Broeckhoven 2004;P r a t ta n d
Rechsteiner 2008). In contrast to UPS, autophagy only
occurs in the cytoplasm and can degrade organelles and
cytoplasmic material as well as damaged proteins. Three
types of autophagy have been identified: macroautophagy,
microautophagy, and chaperone-mediated autophagy (Wong
and Cuervo 2010b). Macrophagy is the major form of
autophagy and begins with the engulfment of cytosolic
material by a double membrane resulting in structures called
autophagosomes. The autophagosomes then fuse with lyso-
somes leading to the degradation of the engulfed material by
lysosomal hydrolases (Wong and Cuervo 2010b). Degrada-
tion of some expanded polyQ proteins via macroautophagy
has been observed (Qin et al. 2006; Ravikumar et al. 2002;
Young et al. 2009), and enhancing this pathway was shown
to ameliorate toxicity in some, but not all polyQ disease
models (Menzies et al. 2010; Nisoli et al. 2010; Ravikumar
et al. 2004; Tanaka et al. 2004).
In this study, we show that both UPS and autophagy
degradation are important to reduce ATXN7 toxicity. How-
ever, the two pathways are used differently to degrade full-
length and cleaved ATXN7 fragments. While full-length
mutant ATXN7 as well as endogenous ATXN7 was primar-
ily found in the nucleus and degraded by UPS in both PC12
and HEK 293T cells, cleaved ATXN7 fragments were
detected in both the nucleus and the cytoplasm and degraded
to a similar level by autophagy and UPS. Furthermore,
pharmacological activation of autophagy ameliorated the
toxic effect of mutant ATXN7 in a novel stable inducible
PC12 cell model. The work presented here suggests that
both UPS and autophagy are important for the clearance of
mutant ATXN7, and enhancing autophagic activity could
potentially be used as a therapeutic strategy in SCA7.
Materials and Methods
Plasmids
Plasmids FLQ10 and FLQ65, encoding N-terminal Flag and
C-terminal myc-tagged full-length ATXN7 referred to as
ATXN7Q10-Myc and ATXN7Q65-Myc, have been previ-
ously reported (Strom et al. 2005). To generate plasmids
FLQ10-pTRE-tight and FLQ65-pTRE-tight encoding N-
terminal FLAG-tagged and C-terminally GFP-tagged full-
length ATXN7 with 10 (ATXN7Q10-GFP) or 65
(ATXN7Q65-GFP) glutamine, respectively, FLAG-ATXN7
was excised from FLQ10 and FLQ65 using SacI and SalI
and ligated into pEGFP-N1 in frame with the C-terminal
GFP tag. FLAG-ATXN7-GFP was then excised from
pEGFP-N1 in two pieces (NheI–SalIa n dSalI–NotI) and
ligated into the pTRE-tight vector (Clontech) digested with
NheI and NotI.
Cell Culture, Transfections, and Generation of Inducible
PC12 Cell Lines
Human Embryonic Kidney 293T (HEK 293T) cells were
maintained in Dulbecco’s modified Eagle’sm e d i u m
(DMEM, Invitrogen) supplemented with 10% fetal bovine
serum (FBS, Invitrogen) and 1% penicillin/streptomycin
(Invitrogen) at 37°C, 5% CO2. For transient transfections,
7×10
5 HEK 293T cells were seeded in six-well plates and
transfected 24 h later using polyethyleneimine (CELLn-
TEC) according to the product protocol.
Stable PC12 cell lines were generated by co-transfecting
the Tet-off PC12 cell line (Clontech) with the FLQ10-
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hygromycin marker (Clontech). Individual hygromycin-
resistant colonies were isolated using 200 μg/ml hygromy-
cin and 200 μg/ml G418. Doxycycline was used at 1 μg/ml
to keep ATXN7-GFP expression off during the selection
process. Screening for clones showing correct inducible
ATXN7 expression was done by removing doxycycline
from the media and western blot of cell extracts. Acquired
PC12 stable cell lines were grown at 37°C and 5% CO2,i n
DMEM (Invitrogen) supplemented with 10% horse serum
(Invitrogen), 5% tet system approved fetal bovine serum
(PAA), 100 μg/ml G418 (Invitrogen), 100 U/ml penicillin
Gs o d i u m ,1 0 0μg/ml streptomycin sulfate (Invitrogen),
100 μg/ml hygromycin (Invitrogen), and 1 μg/ml doxycy-
cline (Sigma) when desired.
Treatments
Autophagy and UPS inhibitors or inducers were used at the
following final concentrations: 200 ng/ml rapamycin
(R0395, Sigma), 10 mM NH4Cl (A0171, Sigma), 200 nM
epoxomycin (E3652, Sigma), 10 mM 3-MA (M9281, Sig-
ma), and 10 mM trehalose (Sc-202368, Santa Cruz). Cells
were treated for 24 or 48 h as indicated in the figures. The
effect of epoxomycin on UPS was verified by detection of
poly-ubiquitinated proteins. The inhibition or stimulation of
autophagy following treatments was confirmed by analysis
of the microtubule-associated protein 1 light chain 3 (LC3)
protein, which when macroautophagy is activated associates
to autophagosomes in its LC3 II cleaved and lipidated form
(Mizushima et al. 2008, 2010; Rubinsztein et al. 2009).
Inhibition of autophagy by 3-MA results in decreased LC3
II levels, while inhibition of autophagy by NH4Cl results in
increased levels due to an arrest in the degradation of auto-
phagosomes. Induction of autophagy by rapamycin results
in increased LC3 II levels.
Cell Lysis, Western Blot, and Calculation of ATXN7
Half-lives
HEK 293T or PC12 cells were harvested with radioimmu-
noprecipitation assay (RIPA) buffer (Millipore) supple-
mented with protease inhibitor cocktail (Sigma) and
phenylmethylsulfonyl fluoride (PMSF, Sigma). The super-
natant which we call the soluble fraction was collected after
centrifugation at 21,000 × g at 4°C for 10 min. Protein
concentrations were determined with Bradford assay (Bio-
Rad) and 10–20 μg of extract was subjected to SDS-PAGE.
Proteins were transferred onto nitrocellulose membrane
(Whatman), blocked in 10% milk-TBST (100 mM Tris-
buffered saline pH 7.4, 0.1% tween-20), and incubated with
primary antibodies in 1% milk-TBST. Membranes were
then washed three times with TBST, incubated with
secondary antibody in 1% milk-TBST, and again washed
three times with TBST. The protein of interest was visual-
ized using SuperSignal West Pico chemiluminescent sub-
strate or SuperSignal West extended duration substrate kits
(Pierce) followed by film exposure or detection by a Chem-
iDoc XRS+ imaging system (Bio-Rad). Primary antibodies
were used at the following concentrations: ATXN7 (SCA7
1-135) (Strom et al. 2005) 1:700, actin (SC-1616, Santa
Cruz) 1:500, ubiquitin (SC-8017 Santa Cruz) 1:500, LC3
(PM036, MBL International) 1:1,000, tubulin (T9026,
Sigma-Aldrich) 1:1,000, and histone H3 (ab1791, Abcam).
Signal intensities of target bands were quantified by Image
lab software (Bio-Rad). The relative intensity of the target
protein in the control and treated samples was acquired by
first normalizing the target band with the corresponding
actin intensity. The normalized intensity in the control or
treated samples was then divided by the sum of the normal-
ized intensities of the target protein in the control and all
treated samples. The quota for the control sample was set to
100% and all treated samples in that experiment were shown
as percent compared to control.
The half-lives, i.e., the time required to reduce the ataxin-
7 content by 50%, were calculated from three separate
experiments using the formula: Mt ¼ M0   1=2 ðÞ
t=T
, where
T 0 the half-life, M0 0 the amount at 0 h, and Mt 0 the
amount at 12 h for soluble ataxin-7 and 288 h for aggre-
gated ATXN7 material.
Filter Trap Assay
Cells were lysed using RIPA buffer and centrifuged at
21,000 × g as described above. After centrifugation, the
supernatant, i.e., the soluble fraction, was removed and the
pellet containing RIPA insoluble material was washed two
times with 1× PBS and resuspended in 50 μl DNaseI reac-
tion buffer containing 4 U of DNaseI enzyme (EN0521,
Fermentas). The resuspended pellet, called the insoluble
fraction, was incubated at 37°C for 1 h, and the Bradford
assay (Bio-Rad) was then used to determine the protein
concentration in the sample. SDS and dithiothreitol (DTT)
were then added to a final concentration of 2% and 100 mM,
respectively, before the sample was heated at 95°C for
5 min. Insoluble fractions were loaded and vacuum-filtered
through a 0.2-μm pore size nitrocellulose (Whatman) mem-
brane using a Bio-Rad dot-blot apparatus. A 0.1% SDS
solution was added to each dot-blot slots twice for washing
and the membrane was then removed from the dot-blot and
blocked in 10% milk-TBST. The membrane was then sub-
jected to immunoblottingu s i n gA T X N 7a n t i b o d ya s
described above. Following immunoblotting, signal intensi-
ties of ATXN7 dots were quantified by Image Lab software
(Bio-Rad) and normalized against the protein concentrations.
J Mol Neurosci (2012) 47:219–233 221For analysis of aggregation during induction (Fig. 1c), the
average intensity from each dot was divided by the sum of the
intensities of ATXN7 from all time points in that experiment.
The results are shown as percent aggregation of the total
aggregation at a certain time point. In all other experiments
where the aggregation in non-treated and treated cells was
compared,theintensity fromtheuntreatedcontrolsamplewas
set to 100%, and all treated samples in that experiment were
shown as percent compared to control.
Cellular Fractionations
FLQ10 or FLQ65 cells, non-induced or induced to express
ATXN7 for 9 days, were resuspended and washed two times
Fig. 1 Mutant ATXN7 aggregates and causes toxicity in a stable
inducible PC12 cell model. a Expression of GFP-tagged ATXN7 with
10 (ATXN7Q10-GFP, left panel) or 65 (ATXN7Q65-GFP, right panel)
glutamines after induction (doxycycline removal) of FLQ10 and
FLQ65 stable PC12 cell lines for the indicated number of days.
Western blot analysis using an ATXN7 antibody detected endogenous
ATXN7, the respective full-length transgenic proteins and cleaved
ATXN7 fragments. Actin was used as loading control. Asterisk indi-
cates background from previous probing. b The expression level of
ATXN7Q10-GFP and ATXN7Q65-GFP is not statistically different in
FLQ10 and FLQ65 cells 12 days after induction. Actin was used for
normalization and quantifications were done from three independent
experiments. c Analysis of ATXN7 aggregation. Cells induced to
express ATXN7Q10-GFP or ATXN7Q65-GFP for the indicated numb-
ers of days were harvested and RIPA insoluble fractions were subjected
to filter trap assay. d Viability of FLQ10 and FLQ65 cells induced to
express ATXN7Q10-GFP or ATXN7Q65-GFP for the indicated num-
ber of days. Viability was measured by WST-1 assay and normalized
against the protein content. e Microscopic analysis of ATXN7 in
induced and non-induced FLQ10 and FLQ65 cells using an ATXN7
antibody (upper panel) and GFP fluorescence (lower panel). Arrows
indicate inclusions. f Cytoplasmic (Cyt) and nuclear (N) proteins were
separated by fractionation and the localization of ATXN7 analyzed by
western blot. For quantifications, all data are shown as means ± SEM
from three independent experiments. ***p<0.001
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PBS was removed and the packed cell volume (PCV) was
estimated. The cells were resuspended in 5xPCV volume of
hypertonic lysis buffer (10 mM HEPES pH 7.9, 1.5 mM
MgCl2, 10 mM KCL, 1 mM EDTA, freshly supplemented
with 0.5 mM DTT, protease inhibitor cocktail (Sigma), and
0.2 mM PMSF (Sigma)) and allowed to swell on ice for
15 min. Cells were collected again by centrifugation as
above and resuspended in 2xPCV volume of hypertonic
buffer, and the plasma membrane was lysed using a 27-
gauge needle. After centrifugation at 11,000 × g at 4°C for
20 min, the supernatant, i.e., the cytoplasmic fraction, was
collected. To obtain the nuclear proteins, the pellet was
further resuspended in a high salt buffer (20 mM HEPES
pH 7.9, 1.5 mM MgCl2, 400 mM NaCl, 20% glycerol,
2 mM EDTA, freshly supplemented with the same inhibitors
as above) for 30 min to lyse the nuclei. After centrifugation
at 20,000 × g for 15 min at 4°C, the supernatant, i.e., the
nuclear fraction, was collected. Protein concentrations were
determined using the Bradford method and fractions were
analyzed using western blot as described above.
WST-1 Cell Viability Test
FLQ10 and FLQ65 cells, non-induced or induced for 0, 2, 5,
8, or 11 days, were seeded into 96-well plates at 2×10
4 cells/
well. The following day, WST-1 assay was performed accord-
ing to the manufacturer’s protocol (630118, Clontech). For
evaluation of the effect of different treatments on viability,
non-inducedorFLQ65cellsinducedfor5dayswereseededat
2×10
4cells/well.Thefollowingday,UPSorautophagyinhib-
itors/activators were applied as described above for 24 or 48 h
before the WST-1 assay was performed. Absorbance (450–
690 nm) was measured on a Digiscan absorbance reader
(Labvision). After the WST-1 assay, the protein concentration
ineachwellwas determinedusing theLowry assay (Bio-Rad)
and cell viability was normalized against the protein concen-
tration. The value obtained from the untreated non-induced
sample was set to 100%.
Microscopy and Inclusion Counting
Non-inducedPC12cellsorPC12cellswithATXN7expression
induced for 5 days were seeded onto gelatin-coated cover slips.
For analysis of GFP fluorescence, cells were allowed to grow
for 72 h before they were washed with PBS, fixed for 30 min in
4% paraformaldehyde in 0.1 M PBS, and analyzed by micros-
copy. For ATXN7 staining and inclusions counting, the indi-
cated inhibitor was added 24 h after seeding and the cells
analyzed after an additional 48 h. For analysis, cover slips were
washedandfixedas describedabove,beforetheywereblocked
in 10% heat-inactivated FBS in 0.1 M PBS with 0.1% Triton
X-100 (PBST) for 30 min. Cover slips were then incubated
with ATXN7 primary antibodies (Strom et al. 2005)d i l u t e d
1:500 in 2% FBS-PBST overnight at room temperature (RT).
Following primary antibody incubation, sections were washed
w i t hP B S Ta n di n c u b a t e dw i t h4 ′,6-diamidino-2-phenylindole
dihydrochoride (Sigma) at 1:7,500 and Alexa fluor 594 anti-
rabbit (Molecular Probes) at 1:300 in 10% FBS-PBST at RT
for 1 h. Cover slips were then washed with PBST and
mounted using a Vectashield-mounting medium. Fluores-
cence microscopy was carried out using a Leica DM IRBE
epifluorescence microscope with a ×100 objective. To quan-
tify the number of cells with inclusions, the total number of
cells and the number of cells with ATXN7-positive inclusions
were counted in 10 randomly chosen view fields (approxi-
mately 200–300 cells) for each treatment in three independent
experiments.
Statistical Analysis
Statistical analysis of western blots, filter trap, and inclusion
counting data were done by one-way ANOVA followed by
Tukey’s post hoc test using GraphPad Prism 5.0.
Results
Expression of Expanded ATXN7 in a Novel Inducible PC12
Cell Line Leads to Aggregation and Toxicity
In order to compare the degradation pathways for wild-type
and mutant ATXN7 and to study the effect of autophagy
activation on mutant ataxin-7-induced toxicity, we con-
structed stable inducible PC12 cell lines expressing N-
terminal FLAG- and C-terminal GFP-tagged human
ATXN7 with 10 or 65 glutamines using the Tet-off expres-
sion system. Using this system, the expression of the
corresponding proteins named ATXN7Q10-GFP and
ATXN7Q65-GFP is induced upon removal of doxycline
from the media. One ATXN7Q10-GFP clone (FLQ10 line)
and one ATXN7Q65-GFP (FLQ65 line) which had similar
induction patterns (Fig. 1a) and expression levels (Fig. 1b)
of the respective transgenic proteins after induction were
chosen for further studies. Clear expression of the transgenic
ATXN7 was detectable from day 6 onwards in both these
cell lines (Fig. 1a). Whereas no ATXN7 aggregation was
detected in ATXN7Q10-GFP cells, analysis of ATXN7Q65-
GFP cells revealed the presence of aggregated ATXN7
material from day 3 onwards using the filter trap method
(Fig. 1c). Viability assays showed that induction of
ATXN7Q65-GFP caused a progressive reduction in viabil-
ity, and 12 days after induction, a 41.3% decrease in viabil-
ity was observed (Fig. 1d). No statistical significant change
in viability was detected in ATXN7Q10-GFP expressing
cells on any day after induction (Fig. 1d).
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antibody SCA7 1-135 (Jonasson et al. 2002; Strom et al.
2002) directed against the ATXN7 N-terminal also detected
endogenous ATXN7, as well as several ATXN7 fragments in
western blot experiments (Fig. 1a). In ATXN7Q10-GFP
expressing cells, high levels of one Q10 fragment between
40 and 50 kDa were observed, whereas two major fragments
around 45 kDa (Q65 fragment 1) and 40 kDa (Q65 fragment
2) were detected in ATXN7Q65-GFP cells. Truncated N-
terminal ATXN7 fragments with similar sizes have been
reported in many other SCA7 models, and caspase-7 cleavage
of ATXN7 at amino acids 266 and 344 has been reported
(Young et al. 2007).
Microscopic analysis revealed low levels of ATXN7 in non-
induced PC12 cell lines; however, after induction, a stronger
predominantly nuclear expression of ATXN7 was detected in
both ATXN7Q10-GFP and ATXN7Q65-GFP expressing cells
(Fig. 1e). The nuclear localization was confirmed by cell frac-
tionations, which revealed the presence of both full-length as
well as Q10 and Q65 fragments in the nuclei after induction
(Fig. 1f). However, the fragments could also be detected in the
cytoplasm. In fact, the larger Q65 fragment 1 was predomi-
nantly detected in the cytoplasm (Fig.1f).Microscopic analysis
of inclusion formation revealed both nuclear and cytoplasmic
ATXN7-positive inclusions in induced FLQ65 cells, with 74.6
±4.3% of ATXN7Q65-GFP expressing cells containing inclu-
sions 8 days after induction (Fig. 1e).
Expansion of the Polyglutamine Domain Increases
the Stability of ATXN7 Through Aggregation
The ability to switch the ATXN7 expression on or off in our
stable PC12 cell models allowed us to compare the stability
and clearance rate of ATXN7 carrying a normal or expanded
repeat without the use of protein synthesis inhibitors like
cycloheximide. This is important since this type of drugs
can interfere with protein degradation (Abeliovich et al.
2000; Lawrence and Brown 1993; Ravikumar et al. 2002).
To compare the stability of ATXN7Q10-GFP and
ATXN7Q65-GFP, the ATXN7 level was analyzed at various
time points after doxycycline was added to the media of
FLQ10 or FLQ65 cells to turn off further ATXN7 expres-
sion. After doxycycline addition, full-length ATXN7Q10-
GFP was progressively cleared from the cells with a half-life
of approximately 4.5 h (Fig. 2a, b). For the Q10 fragment, a
half-life of 4.7 h was observed. In contrast, the level of
soluble full-length ATXN7Q65-GFP increased during the
first 1.5 h after doxycycline addition after which the level
rapidly decreased (Fig. 2a, b). A similar pattern was found
for the two main ATXN7 fragments. The initial increase in
soluble mutant ATXN7 after doxycycline addition suggests
that the mutant protein is more resistant towards degradation
and accumulates. This has also been observed in other
SCA7 models (Yvert et al. 2001). The level of soluble full-
length ATXN7Q65-GFP is determined not only by degra-
dation but also by proteolytic cleavage and aggregation of
the full-length protein. We suspected that the rapid clearance
of soluble forms of ATXN7Q65-GFP starting from 1.5 h
after doxycycline addition could most likely be due to
aggregation rather than degradation. Indeed, analysis of
the level of aggregated ATXN7 material revealed a progres-
sive increase as the levels of soluble forms of ATXN7Q65-
GFP decreased (Fig. 2a, b). Analysis of the stability of the
aggregated ATXN7 material revealed a half-life for clear-
ance of approximately 34.3 h (Fig. 2c). These results show
that although both Q10 and Q65 ATXN7 are cleared away,
expansion of the polyglutamine domain enhances the stabil-
ity of ATXN7 mainly through rapid aggregation.
ATXN7 Carrying a Normal 10Q Repeat Is Primarily
Degraded by the UPS
UPS and autophagy are the two main protein degradation
pathways in mammalian cells. To determine whether these
pathways play a role in the clearance of ATXN7 carrying a
normal repeat, the effect of UPS and autophagy inhibition
on endogenous and transgenic ATXN7Q10 levels was ana-
lyzed (Figs. 3 and 4). We used epoxomycin as a selective
proteasome inhibitor (Garcia-Echeverria 2002; Meng et al.
1999) as other commonly used inhibitors such as MG132,
ALLN, or lactacystin also have been reported to interfere
with autophagic pathways (Abeliovich et al. 2000; Law-
rence and Brown 1993; Ravikumar et al. 2002). Treating
PC12 or HEK 293T cells with epoxomycin led to a statisti-
cal accumulation of endogenous ATXN7 in both cell types
(Figs. 3a and 4a). Similarly, application of the inhibitor to
FLQ10 PC12 cells or transfected HEK 293Tcells decreased
the clearance of transgenic ATXN7Q10. In FLQ10 PC12
cells, a sixfold accumulation of full-length ATXN7Q10-
GFP could be observed after co-treatment with epoxomycin
and doxycycline compared to control cells treated with only
doxycycline (Fig. 3c). A fourfold increase in the major Q10
 Fig. 2 Expansion of the polyglutamine domain stabilizes the ATXN7
protein. a Clearance of soluble full-length ATXN7, soluble ATXN7
fragments, and aggregated ATXN7 material. Doxycycline was added
(turn off) to the media of FLQ10 or FLQ65 cells induced to express
ATX7Q10-GFP or ATXN7Q65-GFP for 10 days and the ATXN7
clearance analyzed during 12 h. Upper panel: ATXN7 western blot
analysis of ATXN7Q10-GFP cell extracts, middle panel: western blot
for ATXN7Q65-GFP cells, and lower panel: filter trap analysis for
ATXN7Q65-GFP cells. b Quantification of the clearance from three
independent experiments. The ataxin-7 intensity was normalized with
actin (loading control) and the average value of 0 h from three inde-
pendent experiments was set to 100%. c Analysis of clearance of
aggregated ATXN7Q65 material during 288 h using the filter trap
assay. Upper panel: a representative blot, lower panel: quantification
of clearance based on three independent experiments. All data are
shown as means ± SEM. *p<0.05
224 J Mol Neurosci (2012) 47:219–233fragment was also observed (Fig. 3a, c). In HEK 293T cells
transfected to express myc-tagged ATXN7Q10, treatment
with epoxomycin for up to 48 h resulted in a circa fourfold
accumulation of full-length ATXN7Q10-Myc and an ap-
proximately threefold increase of the Q10 fragment
(Fig. 4a). In all experiments, the inhibition of UPS was
confirmed by ubiquitin western blot showing accumulation
of poly-ubiquitinated proteins after epoxomycin treatment
(Figs. 3 and 4). Taken together, these data suggest that UPS
is important for the clearance of endogenous as well as
transgenic ATXN7Q10 in both PC12 and HEK 293T cells.
Inhibition of autophagy by either 3-MA, an inhibitor of
macroautophagy initiation (Cuervo et al. 2004; Qin et al.
2003; Seglen and Gordon 1982), or ammonium chloride
(NH4Cl), an inhibitor of lysosomal proteolysis (Cuervo et al.
2004), had no effect on the level of endogenous ATXN7 in
eitherPC12orHEK 293Tcells (Figs.3b, c and 4b).Similarly,
activationofautophagybyrapamycin(Blommaartetal.1995;
Ravikumar et al. 2004; Sarkar etal. 2009) or trehalose (Sarkar
et al. 2007) had no effect on the level of endogenous ATXN7
in either cell line (Figs. 3b, c and 4d; data not shown). These
data suggest that autophagy plays a little role in the degrada-
tion of ATXN7 with a normal repeat. In agreement with this,
no significant decrease in clearance of transgenic
ATXN7Q10-GFP or the Q10 fragment could be observed
after autophagy inhibition in the stable PC12 cells (Fig. 3b).
However, a small but still statistically significant 1.5-fold
accumulation of full-length ATXN7Q10-Myc could be ob-
served in transiently transfected HEK 293Tcells after autoph-
agy inhibition (Fig. 4b and data not shown). In HEK 293T
cells, combined treatment with 3-MA and epoxomycin for
48 h also had an additive effect on the accumulation of full-
length ATXN7Q10-Myc and the Q10 fragment (Fig. 4c).
Furthermore, stimulation of autophagy decreased both the
ATXN7Q10-Myc and Q10 fragment levels (Fig. 4d). The
inhibition or stimulation of autophagy following treatments
was confirmed by analysis of the microtubule-associated pro-
tein 1 LC3 protein; see “Materials and Methods” for more
information (Mizushima et al. 2008, 2010; Rubinsztein et al.
2009).Thesedatasuggestthatautophagyplaysaminorrolein
the degradation of endogenous ATXN7 in both HEK 293T
and PC12 cells, as well as degradation of transgenic
ATXN7Q10-GFP in PC12 cells. The observed contribution
of autophagy to the degradation of ATXN7Q10-Myc in HEK
293T cells could be a result of the high over-expression
acquired after transient transfection or indicate a higher usage
of autophagy in HEK 293Tcells.
Both UPS and Autophagy Influence the Level
of Aggregated Expanded ATXN7
We next focused on the degradation mechanism(s) of ex-
panded ATXN7. Using the stable FLQ65 PC12 cells, we
could observe that UPS inhibition decreased the clearance of
both soluble full-length ATXN7Q65-GFP and Q65 frag-
ments after additional ATXN7 expression had been turned
off (Fig. 5). An approximate three- to fourfold increase of
full-length as well as both major fragments could be
detected in epoxomycin-treated cells compared to control
cells treated with only doxycycline (Fig. 5a). An approxi-
mate 32% increase in aggregated ATXN7 material was also
observed after UPS inhibition in the PC12 cells (Fig. 5b).
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soluble and aggregated ATXN7 in transfected HEK 293T
cells expressing ATXN7Q65-Myc after treatment with
epoxomycin (Fig. 6a and data not shown). Since the aggre-
gated material could not be degraded by UPS (Verhoef et al.
2002), these data suggest that UPS degrades soluble full-
length ATXN7Q65-GFP or cleaved fragments and the in-
crease in these forms of ATXN7 after inhibition results in
increased aggregation.
No significant increase in soluble full-length or ATXN7
fragments was observed after inhibition of autophagy in
PC12 cells (Fig. 5a). However, inhibition of autophagy by
3-MA or NH4Cl did result in increased levels of aggregated
ATXN7 material to a similar degree as UPS inhibition
(Fig. 5b). The increase in aggregated material after autoph-
agy inhibition was confirmed in transfected HEK 293Tcells
expressing ATXN7Q65-Myc (Fig. 6a). In these cells, a clear
additive effect could also be observed upon combined inhi-
bition of UPS and autophagy (Fig. 6a). Furthermore, acti-
vation of autophagy by either rapamycin or trehalose
increased the clearance of aggregated ATXN7 (Fig. 6b).
These data suggest that either cleaved ATXN7Q65-GFP
fragments and/or aggregated ATXN7 material can be
cleared away by autophagy.
Fig. 3 Endogenous ATXN7 and ATXN7Q10-GFP are mainly degrad-
ed by UPS in PC12 cells. Expression of ATXN7Q10-GFP was turned
off (+Dox) in FLQ10 cells induced for 10 days and the level of
endogenous and ATXN7Q10-GFP during 24 h was analyzed in the
absence or presence of UPS inhibition, autophagy inhibition, or
autophagy activation. a Representative western blot analysis of soluble
full-length ATXN7Q10-GFP, endogenous ATXN7, and Q10 fragment
after inhibition of UPS with 200 nM epoxomycin. Probing for poly-
ubiquitinated proteins was done to verify UPS inhibition. b Represen-
tative western blot analysis of soluble full-length ATXN7Q10-GFP,
endogenous ATXN7, and Q10 fragment after autophagy inhibition
with 100 mM 3-MA or 10 mM NH4Cl, as well as autophagy activation
with 200 nM rapamycin. Probing for LC3 II was done to verify the
activation or inhibition of autophagy. c Quantification of ATXN7
levels from three independent western blots as shown in a and b.
The ATXN7 intensity was normalized with actin (loading control)
and the average value of the −Dox control from three independent
experiments was set to 100%. Data are shown as means ± SEM.
*p<0.05; **p<0.01; ***p<0.001
Fig. 4 Autophagy and UPS synergistically regulate transient trans-
fected ATXN7Q10 degradation in HEK 293T cells. The level of
endogenous ATXN7 or ATXN7Q10-Myc in transfected HEK 293 T
cells was analyzed after a 24- or 48-h incubation with UPS inhibition
and/or autophagy inhibition or activation. Non-treated transfected cells
were used as control. a Effect of UPS inhibition. Top panel: a repre-
sentative western blot for full-length (FL) ATXN7Q10-Myc, endoge-
nous ATXN7, and the 40-kDa Q10 fragment. Middle panel:U P S
inhibition was confirmed by probing for poly-ubiquitinated proteins.
Bottom panel: Quantification of ATXN7 after normalization with actin
(loading control) from three independent experiments with non-treated
control cells set to 100%. b Effect of autophagy inhibition with 3-MA.
Top panel: a representative ATXN7 western blot. Middle panel: LC3
probing to verify the effect of 3-MA on autophagy. Bottom panel:
quantification of ATXN7 after normalization with actin (loading con-
trol) from three independent experiments with non-treated control cells
set to 100%. c The effects of combined inhibition of UPS and autoph-
agy on full-length (FL) ATXN7Q10-Myc and the Q10 fragment. Rep-
resentative western blot (top panel) and quantification from three
independent experiments (bottom panel). For quantifications, ATXN7
was normalized with actin (loading control) and non-treated control
cells set to 100%. d Effect of activation of autophagy with rapamycin
or trehalose on endogenous ATXN7, full-length ATXN7Q10-GFP, and
Q10 ATXN7 fragment. Top panels: representative western blots, bot-
tom panels: quantifications from three independent experiments. For
quantifications, ATXN7 was normalized with actin (loading control)
andnon-treatedcontrolcellssetto100%.LC3probingwasdonetoverify
the effect of the treatment on autophagy (middle panels). For all graphs,
data are shown as means ± SEM. *p<0.05; **p<0.01; ***p<0.001
b
226 J Mol Neurosci (2012) 47:219–233Autophagy Is not Up-regulated in Stable ATXN7Q65-GFP
Expressing PC12 Cells
Since we observed that pharmacological activation of
autophagy could help clear away ATXN7Q65, we next
investigated whether expression of mutant ATXN7
resulted in increased endogenous autophagic activity.
However, analysis of the autophagy marker LC3 II
(Mizushima et al. 2010; Rubinsztein et al. 2009)i n
F L Q 6 5P C 1 2c e l l si n d u c e dt oe x p r e s sA T X N 7 Q 6 5 -
GFP for different time lengths revealed no significant
increase in the level of LC3 II suggesting that the PC12
cells have not up-regulated autophagy despite expressing
ATXN7Q65-GFP (Fig. 7).
Fig. 5 Clearance of soluble ATXN7Q65 by UPS but contribution
by autophagy to the reduction of aggregated ATXN7Q65 material
in PC12 cells. Expression of ATXN7Q65-GFP was turned off
(+Dox) in FLQ65 cells induced for 10 days, and the clearance
of ATXN7 during 24 h was analyzed in the absence or presence
of UPS inhibition or autophagy inhibition or activation. a Anal-
ysis of soluble full-length ATXN7Q65-GFP and Q65 fragments 1
and 2. Top panel: a representative western blot, lower panel:
quantification of three independent experiments. For quantifica-
tions, ATXN7 was normalized against actin (loading control). b
Analysis of aggregated ATXN7 material using filter trap assay
after UPS and autophagy inhibition or activation. Top panels:
representative blot, lower panel: quantification of three indepen-
dent experiments with the level in untreated + Dox sample set to
100%. Data are shown as means ± SEM. *p<0.05; **p<0.01;
***p<0001
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ATXN7-Induced Toxicity
To further investigate the role of UPS and autophagy in
ATXN7 turnover and toxicity, the levels of soluble mo-
nomeric and aggregated ATXN7, as well as cell viability,
were compared in FLQ65 PC12 cells allowed to continu-
ously express ATXN7Q65-GFP for 8 days while treated
with or without UPS or autophagy inhibitors/activators for
t h el a s t2 4o r4 8h( F i g .8). Consistent with previous
results, only inhibition of UPS with epoxomycin elevated
the levels of full-length monomeric ATXN7Q65-GFP
when ATXN7 was continuously expressed in PC12 cells
(Fig. 8a). An increase in the level of the Q65 fragment 1,
as well as an increase in aggregated ATXN7 material, was
also observed (Fig. 8a, b). Microscopic analysis further
confirmed the increase in aggregated ATXN7 material
as a 7.65±5.12% increase in the number of cells with
inclusions was observed after UPS inhibition (Fig. 8e).
Analysis of cell viability revealed that UPS inhibition
decreased the viability of ATXN7Q65-GFP cells by
30.1% (Fig. 9a). UPS inhibition also decreased the via-
bility of non-induced FLQ65 cells. However, the effect on
viability was statistically larger in ATXN7Q65-GFP
expressing cells. These data suggest that clearance of
ATXN7Q65-GFP by UPS reduces ATXN7-induced
toxicity.
Similarly to what was observed during the clearance
experiments, neither activation nor inhibition of autophagy
had any effect on monomeric full-length ATXN7Q65-GFP
levels (Fig. 8c). However, inhibition of autophagy by 3-MA
resulted in elevated levels of both Q65 fragments (Fig. 8c)
as well as increased the level of aggregated ATXN7 material
and the number of cells with inclusions by 16.28±3.83%
(Fig. 8d, e). An increase in aggregated ATXN7 material was
also observed after NH4Cl treatment (Fig. 8d). Inhibition of
autophagy by 3-MA or NH4Cl reduced the viability of
ATXN7Q65-GFP expressing cells with 37% and 25%, re-
spectively (Fig. 9a). Autophagy inhibition also affected the
viability of non-induced cells, but the effect was statistically
larger in ATXN7Q65-GFP expressing cells than in non-
induced FLQ65 cells. In contrast, activation of autophagy
with rapamycin decreased the level of aggregation and
restored the viability in ATXN7Q65-GFP expressing cells
to the same level as in non-induced PC12 cells (Figs. 8d and
9b). Together these data suggest that clearance via both UPS
and autophagy is important to decrease the toxicity of mu-
tant ATXN7, and up-regulation of ATXN7 degradation
could be used to ameliorate the toxicity.
Fig. 7 Induction of ATXN7Q65-GFP in PC12 cells does not result in
increased autophagic activity. FLQ65 cells were induced to express
ATXN7Q65-GFP for the indicated number of days before the cells
were harvested and the levels of LC3 I and II analyzed by western blot.
Induction of ATXN7Q65-GFP was verified by ATXN7 probing and
actin was used as loading control. Lower panel shows quantification of
the LC3 II level normalized against actin from three independent
experiments. Data are shown as means ± SEM
Fig. 6 Both UPS and autophagy degrade mutant ATXN7 in HEK
293T cells. HEK 293T cells transfected to express ATXN7Q65-Myc
was treated with UPS and or autophagy inhibitors or activators for 24
or 48 h and the level of aggregated ATXN7 material analyzed. Non-
treated transfected cells were used as control. a Effect of UPS inhibi-
tion with epoxomycin, autophagy inhibition with 3-MA, and combined
treatment with epoxomycin plus 3-MA. Top panel: representative blot,
bottom panel: quantification. b Analysis of aggregated ATXN7 mate-
rial after activation of autophagy by rapamycin (left side) or trehalose
(right side). For all graphs, quantifications were done from three
independent experiments and data are shown as means ± SEM. *p<
0.05; **p<0.01; ***p<0.001; ns not significant
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Expanded polyglutamine proteins have been suggested to be
resistant to UPS degradation and cause toxicity through a
gain-of-function mechanism (Bence et al. 2001; Holmberg
et al. 2004; Jana et al. 2001). Pharmacological activation of
autophagy has been shown to increase the degradation and
ameliorate the toxicity of some but not all polyglutamine
proteins (Menzies et al. 2010; Nisoli et al. 2010; Ravikumar
et al. 2004; Tanaka et al. 2004). To date, few reports inves-
tigating the degradation pathways of ATXN7 and the effect
of autophagy activation on SCA7 toxicity have been
Fig. 8 UPS and autophagy both contribute to the clearance of ATXN7
species in PC12 cells continuously expressing ATXN7Q65-GFP. The
expression of ATXN7Q65-GFP was induced in FLQ65 PC12 cells for
8 days and the cells treated with UPS or autophagy inhibitors or
activators for the last 24–48 h. Induced but non-treated cells were used
as control. a Epoxomycin treatment for 24 h. Top panel: representative
ATXN7 blot, middle panel: probing for poly-ubiquitinated proteins to
verify UPS inhibition, and bottom panel: quantification of ATXN7. b
Analysis of aggregated ATXN7 material after 24 h of UPS inhibition.
Top panel: representative blot, bottom panel: quantification. c Inhibi-
tion of autophagy with 3-MA for 24 h or NH4Cl for 48 h, as well as
activation of autophagy with rapamycin for 48 h. Top panel: represen-
tative ATXN7 western blots, middle panel: probings for LC3 to verify
the effect of the treatment on autophagy, and bottom panel: quantifi-
cation of ATXN7. d Analysis of aggregated ATXN7 material after the
same treatments as in c. Top panel: representative ATXN7 blot, lower
panel quantification. e The number of cells with ATXN7-positive
inclusions after UPS and autophagy inhibition. Non-treated cells were
used as control. All quantifications were done from three independent
experiments, and for analysis of soluble ATXN7 levels, the ATXN7
intensity was normalized against actin (loading control). Data are
shown as means ± SEM. *p<0.05; **p<0.01; ***p<0.001
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inhibitors/activators to determine the role of UPS and
autophagy in the degradation and toxicity of the SCA7
disease protein ATXN7. We show that endogenous and
transgenic ATXN7 carrying a normal Q10 repeat are pri-
marily degraded by the UPS in both HEK 293T and PC12
cells. UPS also had a significant effect on the clearance of
mutant ATXN7Q65 in both cell types. However, a clear
contribution by autophagy in the clearance of cleavage frag-
ments of the mutant protein and aggregated ATXN7 mate-
rial was also observed. Furthermore, pharmacological
activation of autophagy by rapamycin ameliorated mutant
ATXN7Q65-GFP-induced toxicity in a novel stable induc-
ible PC12 cell line.
Proteolytic processing resulting in smaller more toxic
fragments carrying the polyQ domain has been suggested
to contribute to the pathology in several polyQ diseases.
Proteolytic cleavage products of ATXN7 have been found in
SCA7 patients as well as in transgenic models, and caspase-
7 cleavage of ATXN7 at amino acids 266 and 344 has been
identified (Garden et al. 2002; Young et al. 2007; Yvert et al.
2001). In our study, we could observe N-terminal ATXN7
fragments carrying the polyQ domain in western blot
extracts from both transfected HEK 293T cells and stable
inducible PC12 cells. One predominant fragment was seen
in our ATXN7Q10 cells, whereas two main fragments of
approximately 40 and 45 kDa were observed in ATXN7Q65
cells. Taking advantage of the ability to switch the ATXN7
expression off in our novel stable PC12 cell models, we
compared the clearance rate and degradation pathways of
full-length and ATXN7 fragments. We found that full-length
GFP-tagged ATXN7Q10 and the Q10 fragment were de-
graded by UPS and had estimated half-lives of 4.5 and 4.7 h.
These estimated half-lives are consistent with previous stud-
ies indicating a short half-life for wild-type ATXN7 (Yoo et
al. 2003; Yvert et al. 2001). The preferential degradation of
wild-type ataxin-7 by UPS was also confirmed in HEK
293T cells.
Soluble forms of both full-length and fragments of mutant
ATXN7 appeared to be more stable than the respective wild-
type forms, as no clearance but rather an increase was initially
observed after turn off of additional mutant ATXN7 expres-
sion in the PC12 cells. This finding is consistent with a
previous study showing accumulation of soluble ATXN7 in
an animal model (Yvert et al. 2001). However, after a few
hours,wecould observe a rapid clearance ofboth soluble full-
lengthand mutant fragments inour PC12cells.Thisclearance
is most likely due to aggregation, as we could observe a
progressive increase in aggregated ATXN7 material during
the same time period. The half-life of aggregated ATXN7
material (full-length and/or fragments) was estimated to be
approximately 34h showing that aggregation isa major factor
in stabilizing mutant ATXN7 against degradation.
Interestingly, UPS and autophagy inhibition had different
effects on the various species of mutant ATXN7. While UPS
inhibition increased the levels of soluble full-length and
ATXN7 fragments as well as aggregated ATXN7 material,
autophagy inhibition only affected the levels of ATXN7
fragments and aggregated material. This difference was
observed in both the stable PC12 and the HEK 293T cells.
These data suggest that UPS is the main pathway for deg-
radation of full-length mutant ATXN7, while both UPS and
autophagy contribute to clearance of ATXN7 fragments.
This is perhaps not surprising, as we could show with cell
Fig. 9 Pharmacological activation of autophagy ameliorates the
ATXN7Q65 toxicity. The viability of non-induced or FLQ65 cells
induced to express ATXN7Q65-GFP for 8 days while treated with
inhibitors or activators for the last 24–48 h as indicated in the figure
was analyzed. As controls, non-induced or induced non-treated cells
were used. The cell viability was analyzed using the WST-1 assay and
normalized against the protein concentration. a The induction of
ATXN7Q65-GFP expression caused an approximately 20% decrease
in cell viability compared to the non-induced control. Treatment of
ATXN7Q65-GFP expressing cells with the UPS inhibitor epoxomycin
or the autophagy inhibitors 3-MA and NH4Cl leads to a further circa
30.1%, 37.0%, and 25.0% decrease in cell viability. Decreases in cell
viability were also seen after treatment of non-induced FLQ65 cells;
however, the effect of inhibitors was statistically greater in
ATXN7Q65-GFP expressing cells. b Treatment of ATXN7Q65-GFP
expressing cells with the autophagy activator rapamycin for 24 or 48 h
restored viability of the ATXN7Q65-GFP cells to the same level as in
non-expressing ATXN7Q65-GFP cells. All quantifications were done
with data from three independent experiments and data are shown as
means ± SEM. *p<0.05; ***p<0.001
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predominantly localized to the nucleus which is devoid of
autophagy. In contrast, ATXN7 fragments were shown to
localize to the cytoplasm as well as the nucleus and thereby
be accessible to the autophagic machinery. Our finding that
ATXN7 fragments can be degraded by both UPS and
autophagy is in contrast to the findings of Mookerjee et al.
who found that neither UPS nor autophagy inhibition had
any effect on a mutant ATXN7 fragment transiently
expressed in HEK 293T cells (Mookerjee et al. 2009). This
discrepancy could be due to the processing of full-length
ATXN7 in our cells resulting in different fragments from the
one expressed in their study or their longer 92Q repeat
domain. The proteolytic cleavage of ATXN7 has been sug-
gested to occur in the nucleus and result in the entrapment of
the fragments in the nucleus as they are devoid of any
nuclear export signal (Young et al. 2007). Nuclear entrap-
ment would prevent autophagic degradation of ATXN7
fragments. However, this does not seem to be the case in
our PC12 cell model, possibly since we have a relatively
short polyQ expansion and the fragments produced are
small enough to diffuse through the nuclear pore complexes.
Despite the different effects UPS and autophagy inhibi-
tion had on the level of soluble full-length mutant ATXN7,
inhibition of both systems resulted in a similar worsening of
ATXN7-induced toxicity. As both treatments caused eleva-
tion in Q65 fragments and aggregated ATXN7 material, this
suggests that these species are more toxic than the soluble
full-length protein. This is in agreement with Young et al.
who showed that expression of truncated ATXN7 fragments
caused more aggregation and higher toxicity than expres-
sion of full-length ATXN7 in HEK 293T cells (Young et al.
2007). This idea is further supported by our finding that
autophagy activation by rapamycin, an mTOR-dependent
activator of autophagy (Sarkar et al. 2009), could decrease
the levels of aggregated ATXN7 material and ameliorate
ATXN7-induced toxicity in our PC12 cell model. This was
done without a change in the expression level of soluble
full-length ATXN7 indicating that the effect of rapamycin
was through the activation of autophagy and not by decreas-
ing ATXN7 protein synthesis as have been reported to occur
with the huntingtin protein in an HD model (King et al.
2008). An increase in LC3-positive puncta indicating an
induction of autophagy activity has been reported in SCA7
transgenic mice (Mookerjee et al. 2009). However, we could
not see any signs of increased endogenous autophagy activ-
ity after induction of mutant ATXN7 expression in our
stable PC12 cells (Fig. 7). Why the cells do not up-
regulate the autophagic activity to protect against the
ATXN7 toxicity in our model is unclear. Failure to activate
autophagy has been reported in several other neurodegener-
ative disorders (Wong and Cuervo 2010a), but the mecha-
nism behind this is still unclear.
In conclusion, our study shows that both UPS and
autophagy are important for the clearance of mutant ATXN7
and thereby reduce ATXN7-induced toxicity. While clear-
ance of full-length mutant ATXN7 is primarily performed
by UPS, autophagy contributes to the clearance of mutant
ATXN7 fragments and possibly ATXN7 aggregates. Fur-
thermore, pharmacological activation of autophagy amelio-
rated the ATXN7 toxicity in our model and might be used as
a therapeutic strategy in SCA7.
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